New Zealand markets close in 3 hours 9 minutes

Neuren Pharmaceuticals Limited (NEU.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
19.26+0.17 (+0.92%)
As of 11:30AM AEST. Market open.
Full screen
Previous close19.09
Open19.08
Bid19.24 x 1214500
Ask19.28 x 938700
Day's range18.54 - 19.30
52-week range10.02 - 25.95
Volume64,428
Avg. volume506,525
Market cap2.503B
Beta (5Y monthly)2.01
PE ratio (TTM)16.05
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome

    Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across multiple efficacy measures. Improvements were consistently seen across many of the core PMS characteristics. PMS has severe quality of life impacts for those living with the syndrome, as well as parents and siblings. There are no approved treatme